Skip to main content

Table 1 Formulation of Product

From: Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial

Dose Groups Peptides loaded / HLA class Peptide loading method and concentration DEX dose (expressed as numbers of MHC class II molecules)
A MAGE A3 (168–176) / class I Indirect (10 μg/mL) 0.13 × 1014
  MAGE A3 (247–258) / class II Indirect (10 μg/mL)  
  tetanus toxoid / class II Indirect (10 μg/mL)  
B MAGE A3 (168–176) / class I Indirect (10 μg/mL) 0.4 × 1014
  MAGE A3 (247–258) / class II Indirect (10 μg/mL)  
C MAGE A3 (168–176) / class I Direct (10 μg/mL) 0.13 × 1014
  MAGE A3 (247–258) / class II Indirect (10 μg/mL)  
  tetanus toxoid / class II Indirect (10 μg/mL)  
D MAGE A3 (168–176) / class I Direct (100 μg/mL) 0.13 × 1014
  MAGE A3 (247–258) / class II Indirect (10 μg/mL)